MARKET

MDNAF

MDNAF

Medicenna Therapeutics Corp
OTCQX
0.751
-0.044
-5.53%
Closed 14:55 12/18 EST
OPEN
0.774
PREV CLOSE
0.795
HIGH
0.774
LOW
0.751
VOLUME
12.41K
TURNOVER
9.48K
52 WEEK HIGH
1.400
52 WEEK LOW
0.586
MARKET CAP
57.40M
P/E (TTM)
-6.1658
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MDNAF last week (1208-1212)?
Weekly Report · 4d ago
Medicenna’s MDNA11 Shows Promising Results in Advanced Tumor Trials
TipRanks · 12/10 13:41
Medicenna Therapeutics presents updated clinical data on MDNA11
TipRanks · 12/10 12:45
Medicenna Reports Promising MDNA11 Phase 1/2 Trial Results in Advanced Solid Tumors
Reuters · 12/10 12:30
MEDICENNA UPDATES MDNA11 CLINICAL TRIAL RESULTS AT THE ESMO-IO CONGRESS 2025, FURTHER BOLSTERING ITS ANTI-TUMOR ACTIVITY IN ADVANCED SOLID TUMORS
Reuters · 12/10 12:30
Medicenna Therapeutics to Host Webinar on MDNA11 Clinical Data
TipRanks · 12/09 22:40
Medicenna Therapeutics Hosts Live Webinar to Present Updated MDNA11 Clinical Data
Reuters · 12/09 22:04
Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Updated MDNA11 Clinical Data
Barchart · 12/09 16:04
More
About MDNAF
Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Its IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials, including a Phase IIb trial for recurrent glioblastoma (GBM). Its early-stage high-affinity IL-2B biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Its early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.

Webull offers Medicenna Therapeutics Corp stock information, including OTCQX: MDNAF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDNAF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDNAF stock methods without spending real money on the virtual paper trading platform.